These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25322440)

  • 61. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Strengthening the understanding of the relationship between survival designs and test statistics.
    Ma G; Ganju J
    Pharm Stat; 2010; 9(2):113-24. PubMed ID: 19507135
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 64. On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout.
    Li L; Tang S; Jiang L
    Stat Med; 2017 May; 36(10):1532-1547. PubMed ID: 28110508
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past.
    Benoit A; Legrand C; Dewé W
    Pharm Stat; 2015; 14(4):294-301. PubMed ID: 25924929
    [TBL] [Abstract][Full Text] [Related]  

  • 66. On the importance of accounting for competing risks in pediatric brain cancer: II. Regression modeling and sample size.
    Tai BC; Grundy R; Machin D
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1139-46. PubMed ID: 20472355
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
    Ibrahim JG; Chen MH; Xia HA; Liu T
    Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
    Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
    J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assurance for clinical trial design with normally distributed outcomes: Eliciting uncertainty about variances.
    Alhussain ZA; Oakley JE
    Pharm Stat; 2020 Nov; 19(6):827-839. PubMed ID: 32537910
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sample size and interim analysis issues for dose selection.
    Lee KL
    Am Heart J; 2000 Apr; 139(4):S161-5. PubMed ID: 10740124
    [No Abstract]   [Full Text] [Related]  

  • 74. A unified theory for sequential clinical trials.
    Whitehead J
    Stat Med; 1999 Sep 15-30; 18(17-18):2271-86. PubMed ID: 10474138
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The group sequential triangular test for phase II cancer clinical trials.
    Bellissant E; Bénichou J; Chastang C
    Am J Clin Oncol; 1996 Aug; 19(4):422-30. PubMed ID: 8677918
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sample size for testing difference between two proportions for the bilateral-sample design.
    Qiu SF; Tang NS; Tang ML; Pei YB
    J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.